Small-cell lung cancer

By Megan Lee. Updated by Laura Boyd

Small-cell lung cancer (SCLC) is an aggressive subtype accounting for approximately 15% of lung cancers and is strongly linked to smoking.¹ It is characterized by rapid growth, early metastasis, and initial sensitivity to systemic therapy, although relapse is common and prognosis remains poor.^2,3

What are the key risk factors associated with SCLC?

Smoking is the primary risk factor for SCLC, with 95% of patients having a history of tobacco use. Although smoking cessation reduces risk, incidence remains elevated for >30 years after quitting.³

How is SCLC typically diagnosed?

SCLC is typically diagnosed through chest imaging, such as X-ray or computed tomography (CT), often revealing a central tumor with hilar or mediastinal lymphadenopathy. Confirmation is achieved via biopsy of the primary tumor or involved lymph nodes.⁴ Approximately 15% of patients have brain metastases at diagnosis.⁴

How is SCLC classified and staged?

SCLC is traditionally classified using the Veterans Administration Lung Study Group (VALSG) method into limited-stage disease(LS-SCLC), confined to a hemithorax and treatable within a radiotherapy field, and extensive-stage disease (ES-SCLC), which reflects metastatic spread, and accounts for most cases at diagnosis.^1,5

Tumor node metastasis (TNM) staging is increasingly used alongside the VALSG method to refine prognosis and guide treatment.⁵

What are current treatment approaches?

LS-SCLC is managed with concurrent chemoradiotherapy, with surgery rarely used.⁶ ES-SCLC is treated with platinum–etoposide chemotherapy plus immune checkpoint inhibitors, followed by maintenance immunotherapy.^6,7 Relapse, options include chemotherapy rechallenge or second-line agents.⁷

Why is prognosis poor in SCLC?

Despite initial responses, most patients relapse rapidly.³ Progression-free survival is typically 5 months, and median overall survival for extensive-stage disease remains approximately 12–13 months,⁸ highlighting a substantial unmet need for more effective therapies.

References

1. Wang, 2019. Current diagnosis and management of small-cell lung cancer. https://www.doi.org/10.1016/j.mayocp.2019.01.034
2. Herzog, 2021. Overcoming chemotherapy resistance in SCLC. https://www.doi.org/10.1016/j.jtho.2021.07.018
3. Wang, 2023. SCLC: Epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. https://www.doi.org/10.1016/j.jtho.2022.10.002
4. Kim, 2025. Small cell lung cancer: A review. https://www.doi.org/10.1001/jama.2025.0560
5. Johal, 2021. Real-world treatment patterns and outcomes in small-cell lung cancer: A systematic literature review. https://www.doi.org/10.21037/jtd-20-3034
6. NIH, 2025. Small cell lung cancer treatment (PDQ^®). https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq
7. Behrouzi, 2025. State of the art in treatment of small cell lung cancer. https://www.doi.org/10.1177/17588359251363518
8. Zhai, 2025. Current and future therapies for small cell lung carcinoma. https://www.doi.org/10.1186/s13045-025-01690-6

Developed by EPG Health for Medthority, independently of any sponsor.